Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Operating Income: 2013-2024

Historic Operating Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$299.0 million.

  • Viridian Therapeutics, Inc.\DE's Operating Income rose 52.07% to -$40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$328.1 million, marking a year-over-year decrease of 15.93%. This contributed to the annual value of -$299.0 million for FY2024, which is 17.52% down from last year.
  • Viridian Therapeutics, Inc.\DE's Operating Income amounted to -$299.0 million in FY2024, which was down 17.52% from -$254.4 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Operating Income ranged from a high of -$79.7 million in FY2021 and a low of -$299.0 million during FY2024.
  • Its 3-year average for Operating Income is -$229.3 million, with a median of -$254.4 million in 2023.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Operating Income tumbled by 162.94% in 2020 and then grew by 27.77% in 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Operating Income (Yearly) stood at -$110.4 million in 2020, then grew by 27.77% to -$79.7 million in 2021, then plummeted by 68.45% to -$134.3 million in 2022, then tumbled by 89.46% to -$254.4 million in 2023, then decreased by 17.52% to -$299.0 million in 2024.